Quince Therapeutics, Inc. 8-K

What Happened Quince Therapeutics announced on April 22, 2026 that its Board increased to four members and appointed June Bray as a Class I, independent director effective immediately. Ms. Bray will serve until the 2026 Annual Meeting of Stockholders (or earlier if she resigns, is removed, or disqualified) and has been assigned to the Nominating & Governance, Audit, and Compensation Committees.

Key Details

• Board change: size increased to four directors; appointment effective April 22, 2026.
• Committee assignments: Nominating & Governance, Audit, Compensation.
• Independence and disclosures: Board determined Ms. Bray is independent under Nasdaq rules; no family relationships or related-party transactions requiring disclosure.
• Compensation: will receive standard non-employee director cash retainers under the company’s Outside Director Compensation Policy (no option grant on appointment). Annual retainers: $38,000 (board) + $7,500 (Nominating & Governance) + $5,500 (Audit) + $4,000 (Compensation). She will sign the company’s standard indemnification agreement.

Why It Matters This is a governance update that affects board composition and committee oversight. Investors should note the addition of an independent director to key committees (audit, compensation, nominating & governance) and the cash retainer costs associated with her service. The filing contains no disclosure of related-party transactions or special compensation beyond the company’s stated director policy.